Unsaturated Hydroxamic Acid Derivatives and Their Use for the Treatment and Prevention of an Ammonia-Associated Disease or Disorder

Abstract

The present disclosure provides an enteral or urinary pharmaceutical formulation comprising (A) a compound of formula I, (I), wherein R1 is a C1-C3 alkyl; X is —C(R2)(R3)—C(R4)(R5)— or —C≡C—, wherein R2, R3, R4, and R5 are each independently H or In methyl; Y is —CH═CH—CH2—, —CH2—CH═CH—; —C≡C—CH2; —CH2—C≡C—; or —C(R7)(R8)—C(R9)(R10)—C(R11)(R12)—, wherein R7, R8, R9, R10, R11 and R12, are each independently H or methyl; provided that (1) when X is —C≡C—, Y is —C(R7)(R8)—C(R9)(R10)—C(R11)(R12)— and that (2) when Y is not —C(R7)(R8)—C(R9)(R10)—C(R11)(R12)—, X is —C(R2)(R3)—C(R4)(R5)—; and R6 is H or CH3, or a stereoisomer or a mixture thereof, or a pharmaceutically acceptable salt, ester or solvate thereof; and (B) (a) at least one pharmaceutically acceptable excipient; or (b) at least one other therapeutic agent; or (c) a combination of (a) and (b); and a use thereof for the treatment or prevention of an ammonia-associated disease or disorder, or a symptom thereof.

Dependencies are inferred from the claim text.